Methods for enhancing immunosuppressive therapy by multiple administration of αβTCR-binding polypeptide

US11142575B2 · kind B2 · utility

Assignees

• Genzyme Corporation · US
• Eberhard Karls Universität Tübingen · DE

Inventors

• Gregor Blank · Tübingen, DE
• Rupert Handgretinger · Tübingen, DE
• Karin Schilbach · Tübingen, DE
• Gina Lacorcia · Concord, US
• Daniel Snell · Thalwil, CH
• Andreas Menrad · Berlin, DE

Key dates

• Filing date: Oct 30, 2014
• Grant date: Oct 12, 2021
• Expiry date: May 1, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/75
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-αβ-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibodies and/or fragments thereof) to reduce αβ T cells in the subject relative to γδ cells in the subject are provided.